Antivirals — API & Bulk Drug Suppliers in India

azapeptide HIV protease inhibitor — capsule formulations for HIV-1, boosted with ritonavir.

integrase strand-transfer inhibitor — tablet formulations, the backbone of modern HIV therapy.

non-nucleoside reverse-transcriptase inhibitor — tablet formulations in first-line antiretroviral therapy.

nucleoside reverse-transcriptase inhibitor — capsule and combination formulations for HIV and PrEP.

RNA-polymerase inhibitor — tablet formulations under emergency-use protocols for viral infections.

HIV protease inhibitor — tablet formulations co-formulated with ritonavir.

SARS-CoV-2 protease inhibitor — tablet formulations co-packed with ritonavir for COVID-19.

neuraminidase inhibitor — capsule and suspension formulations for influenza treatment.

HIV protease inhibitor and booster — tablet formulations as the pharmacokinetic booster of antiretroviral regimens.

nucleoside reverse-transcriptase inhibitor — tablet and syrup formulations for HIV, including prevention of mother-to-child transmission.

nucleoside reverse-transcriptase inhibitor — tablet and solution formulations for HIV-1, typically with lamivudine.

adamantane antiviral and dopaminergic — capsule formulations for influenza A and adjunct use in Parkinson's disease.

integrase strand-transfer inhibitor — single-tablet regimen component for HIV-1.

non-nucleoside reverse-transcriptase inhibitor — tablet formulations for HIV-1 therapy.

HCV NS5A inhibitor — tablet formulations, with grazoprevir, for hepatitis C.

non-nucleoside reverse-transcriptase inhibitor — tablet formulations for treatment-experienced HIV patients.

prodrug of penciclovir — tablet formulations for herpes zoster and genital herpes.

nucleoside-analogue antiviral — capsule and injection formulations for CMV disease.

HCV NS3/4A protease inhibitor — tablet formulations, with pibrentasvir, for pan-genotypic hepatitis C.

HCV NS3/4A protease inhibitor — tablet formulations, with elbasvir, for hepatitis C.

immune-response modifier — cream formulations for genital warts and actinic keratosis.

ribonucleoside-analogue antiviral — capsule formulations for early COVID-19 under authorised protocols.

non-nucleoside reverse-transcriptase inhibitor — tablet and suspension formulations for HIV-1 therapy.

HCV NS5A inhibitor — tablet formulations, with glecaprevir, for pan-genotypic hepatitis C.

integrase strand-transfer inhibitor — tablet formulations for HIV-1 therapy.

non-nucleoside reverse-transcriptase inhibitor — tablet formulations in second-line antiretroviral regimens.

HCV NS3/4A protease inhibitor — tablet formulations in hepatitis C combination therapy.

first-generation nucleoside herpes antiviral — tablet, cream and injection formulations for HSV and VZV.

NS5A inhibitor for hepatitis C — tablet formulations within HCV direct-acting regimens.

second-generation protease inhibitor — tablet formulations for HIV-1 therapy.

guanosine analogue for hepatitis B — tablet formulations for chronic hepatitis B.

nucleoside reverse transcriptase inhibitor — tablet and solution formulations for HIV and hepatitis B.

NS5A inhibitor for hepatitis C — tablet formulations in sofosbuvir combination therapy.

CCR5 antagonist antiretroviral — tablet formulations within individualised HIV regimens.

nucleotide analogue antiviral — injection formulations for hospitalised viral infections.

NS5B polymerase inhibitor for hepatitis C — tablet formulations as the backbone of HCV direct-acting regimens.

targeted prodrug of tenofovir — tablet formulations for HIV and hepatitis B with a improved renal profile.

nucleotide reverse transcriptase inhibitor — tablet formulations for HIV and hepatitis B, alone and in combinations.

prodrug of acyclovir with higher oral exposure — tablet formulations for herpes zoster, HSV and CMV prophylaxis.

pan-genotypic NS5A inhibitor — tablet formulations in sofosbuvir combination therapy for all HCV genotypes.